A major pharmaceutical company is giving SAS $9 million and three years to improve its data management platform. On March 1, SAS announced a global licensing agreement with AstraZeneca for software to help AstraZeneca meet its strategic goals. AstraZeneca currently uses SAS software in 24 countries, primarily for clinical research and development. The new license will allow AstraZeneca to use the software for drug portfolio management – the identification of compounds that are most likely to become marketable drugs. AstraZeneca also plans to use SAS software for strategic performance management and sales and marketing.

Register or login for access to this item and much more

All Information Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access